论文部分内容阅读
目的加强kallistatin(Kal)这一多功能内源性抗血管生成因子抗肿瘤活性。方法将其他多个基因与Kal联合应用,利用脂质体将带有目的基因的质粒转染入内皮细胞和肿瘤细胞,分析多基因联合治疗对细胞特性的影响。结果 Kal对肺癌细胞A549、NCI-H446、SPC-A1都具抑制作用。Kal与Trail或vasostatin(Vas)联合,可加强对SPC-A1细胞的抑制作用,但三者联合该抑制作用并未进一步加强。Kal与angiostatin(Ang)、Vas联合应用可显著增强对血管内皮细胞EVC304生长、迁移以及小管形成的抑制作用。结论 Kal基因可与多种类型的基因联合作用,增强对肿瘤细胞和血管内皮细胞的抑制作用,为肿瘤的多基因联合治疗提供了实验基础。
Objective To enhance the antitumor activity of kallistatin (Kal), a multifunctional endogenous antiangiogenic factor. Methods A number of other genes were used in combination with Kal. The plasmids with the target gene were transfected into endothelial cells and tumor cells by liposomes, and the effect of multi-gene combination therapy on cell characteristics was analyzed. Results Kal had inhibitory effects on A549, NCI-H446 and SPC-A1 cells. Kal combined with Trail or vasostatin (Vas) can enhance the inhibitory effect on SPC-A1 cells, but the combined effects of these three inhibitors have not been further strengthened. Kal combined with angiostatin (Ang) and Vas could significantly inhibit the growth, migration and tubule formation of vascular endothelial cells (EVC304). Conclusion Kal gene can be combined with various types of genes to enhance the inhibitory effect on tumor cells and vascular endothelial cells and provide the experimental basis for multi-gene combination therapy of tumors.